HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.

Abstract
In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy. The analysis included 12 trials of 94 338 patients. The analysis of trials involving an amlodipine group showed that amlodipine provided more protection against stroke and myocardial infarction than other antihypertensive drugs, including angiotensin receptor blockers (-19%, P<0.0001 and -7%, P=0.03) and placebo (-37%, P=0.06 and -29%, P=0.04). The analysis of trials involving an angiotensin receptor blocker group showed contrasting results between trials versus amlodipine and trials versus other antihypertensive drugs for stroke (+19% versus -25%; P<0.0001) and myocardial infarction (+21% versus +1%; P=0.03). The results of 3 trials comparing an angiotensin receptor blocker with placebo were neutral (P> or =0.14). The within-trial between-group difference in achieved systolic pressure ranged from -1.1 to +4.7 mm Hg for trials involving an amlodipine group and from -2.8 to +4.0 mm Hg for trials involving an angiotensin receptor blocker group. The metaregression analysis correlating odds ratios with blood pressure differences showed a negative relationship (regression coefficients: -3% to -8%), which reached statistical significance (regression coefficient: -6%; P=0.01) for stroke in trials involving an amlodipine group. In conclusion, blood pressure differences largely accounted for cardiovascular outcome.
AuthorsJi-Guang Wang, Yan Li, Stanley S Franklin, Michel Safar
JournalHypertension (Dallas, Tex. : 1979) (Hypertension) Vol. 50 Issue 1 Pg. 181-8 (Jul 2007) ISSN: 1524-4563 [Electronic] United States
PMID17502490 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Amlodipine
Topics
  • Aged
  • Amlodipine (therapeutic use)
  • Angiotensin II Type 1 Receptor Blockers (therapeutic use)
  • Antihypertensive Agents (therapeutic use)
  • Coronary Artery Disease (drug therapy)
  • Diabetic Nephropathies (drug therapy)
  • Female
  • Humans
  • Hypertension (drug therapy)
  • Male
  • Middle Aged
  • Myocardial Infarction (drug therapy, prevention & control)
  • Randomized Controlled Trials as Topic
  • Regression Analysis
  • Stroke (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: